To improve the drug development process by supporting more efficient research and development cooperation among academia, SMEs and the biopharmaceutical industry.
Description:IMI 2 continues the former IMI programme financed under FP7 programme. The scope of the initiative will be expanded to all areas of life science research and innovation, that has been identified as of public health interest, by the World Health Organisation report on priority medicines for Europe and the World. IMI2 brings together companies, universities, public laboratories, innovative SMEs, patient groups and regulators. Objectives * To increase the success…For more information, please connect.
According to the call
Beneficiaries: Administrations States, Agencies Chambers, Corporations, Federations Unions, Research centres, SMEs
Sectors: Education - Training, Health, Industry, Innovation, New technologies
Regions: Balkans, Candidate countries, Developing countries, European Economic Area, European Union, Mediterranean countries, New Independant States, Switzerland